NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ) Is Down 5.7% After Strong Ziihera Phase 3 Data - Has The Bull Case Changed?
Jazz Pharmaceuticals recently reported positive Phase 3 HERIZON-GEA-01 results for its HER2-targeted therapy Ziihera (zanidatamab-hrii) in combination with chemotherapy, showing a statistically significant survival benefit over trastuzumab plus chemotherapy in adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
By positioning Ziihera as a potential new standard of care and supporting an upcoming FDA submission, this data could meaningfully reshape Jazz’s...